BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 15544694)

  • 1. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999-2002).
    Martin K; Lawson-Ayayi S; Miremont-Salamé G; Blaizeau MJ; Balestre E; Lacoste D; Ragnaud JM; Malvy D; Dupon M; Mercié P; Schaeverbeke T; Haramburu F; Dabis F;
    HIV Med; 2004 Nov; 5(6):421-6. PubMed ID: 15544694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
    Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
    Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.
    Bolhaar MG; Karstaedt AS
    Clin Infect Dis; 2007 Jul; 45(2):254-60. PubMed ID: 17578788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
    Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
    Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
    AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis in six HIV-infected patients receiving highly active antiretroviral therapy.
    Molia AC; Strady C; Rouger C; Beguinot IM; Berger JL; Trenque TC
    Ann Pharmacother; 2004 Dec; 38(12):2050-4. PubMed ID: 15507502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
    Mary-Krause M; Billaud E; Poizot-Martin I; Simon A; Dhiver C; Dupont C; Salmon D; Roudiere L; Costagliola D;
    AIDS; 2006 Aug; 20(12):1627-35. PubMed ID: 16868444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
    Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
    HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.
    Ledergerber B; Furrer H; Rickenbach M; Lehmann R; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Egger M; Weber R;
    Clin Infect Dis; 2007 Jul; 45(1):111-9. PubMed ID: 17554711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus.
    Monier P; McKown K; Bronze MS
    Clin Infect Dis; 2000 Dec; 31(6):1488-92. PubMed ID: 11096017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone disorders in human immunodeficiency virus infection.
    Glesby MJ
    Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France.
    Lawson-Ayayi S; Bonnet F; Bernardin E; Ragnaud JM; Lacoste D; Malvy D; Blaizeau MJ; Miremont-Salamé G; Dupon M; Mercié P; Dabis F;
    Clin Infect Dis; 2005 Apr; 40(8):1188-93. PubMed ID: 15791521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
    Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
    Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
    Fardet L; Mary-Krause M; Heard I; Partisani M; Costagliola D;
    HIV Med; 2006 Nov; 7(8):520-9. PubMed ID: 17105511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan.
    Ho YC; Shih TT; Lin YH; Hsiao CF; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
    Jpn J Infect Dis; 2007 Nov; 60(6):382-6. PubMed ID: 18032839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
    Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
    Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.